Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) has provided an update.
Zylox-Tonbridge Medical Technology Co., Ltd. reported a substantial increase in revenue for the year ended December 31, 2024, achieving a 48.3% growth compared to the previous year. This growth was driven by high sales in both neurovascular and peripheral vascular interventional devices, with notable increases in product penetration and market access. The company also reported a non-IFRS adjusted net profit of RMB124.0 million, reflecting enhanced operational efficiency and strategic focus on organic revenue growth.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a company incorporated in the People’s Republic of China, focusing on the medical technology industry. The company specializes in the development and commercialization of interventional medical devices, with a significant emphasis on neurovascular and peripheral vascular interventional products.
YTD Price Performance: 39.23%
Average Trading Volume: 141
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €611.5M
For an in-depth examination of 2190 stock, go to TipRanks’ Stock Analysis page.